Efimosfermin Leads to Significant MASH Improvement

SAN DIEGO — Boston Pharmaceuticals’ once-monthly efimosfermin alfa (formerly BOS-580) prescribed for metabolic dysfunction–associated steatohepatitis (MASH) with F2 and F3 fibrosis significantly improved MASH resolution and fibrosis after 24 weeks, according to results of a phase 2 trial presented at Digestive Disease Week (DDW) 2025. An analogue of the fibroblastContinue Reading

Endoscopic Procedure Shows Promise in Type 2 Diabetes Care

A novel investigational endoscopic procedure targeting the duodenum appears beneficial in improving glycemic parameters in people with type 2 diabetes (T2D). In a new dose-finding study, the re-cellularization via electroporation therapy (ReCET, Endogenex) improved insulin sensitivity, beta-cell function, and other glycemic parameters at 12 and 48 weeks in 51 individualsContinue Reading

Washington, D.C., May 8, 2025) – U.S. Secretary of Agriculture Brooke Rollins will visit the United Kingdom May 12-14. This comes after President Donald J. Trump announced today, on the 80th anniversary of Victory in Europe, a new trade agreement in principle that will lower tariffs…Read MoreContinue Reading

Low Childhood Vitamin D Signals High CVD Risk in Adulthood

TOPLINE: Levels of 25-hydroxy (OH) vitamin D below 37 nmol/L during childhood were significantly associated with an increased risk for adult-onset atherosclerotic cardiovascular disease (CVD) events. METHODOLOGY: Researchers analysed data from a prospective study in Finland to evaluate the relationship between low levels of vitamin D during childhood and adult-onsetContinue Reading